Mark Alles, former CEO of Celgene, testifies by video conference before the House Committee on Oversight and Reform on Wednesday (Pool via AP)
Dems slam drug pricing strategies as 18-month probe comes to an end
The House Oversight Committee held a pair of hearings this week on drug prices. And the Democrats on the panel did not hold back.
Executives from Bristol Myers Squibb (and Celgene), Teva, Amgen, Novartis and Mallinckrodt testified before Congress in the culmination of an 18-month investigation into rising drug prices. The proceedings, built on work from the late Elijah Cummings, produced more than one million documents from the companies and largely concluded that profit was the main driving force behind the increases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
